Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 10, 2020

OrbusNeich signs heart valve product distribution agreement

Hong Kong-based OrbusNeich Medical and P+F Products + Features have signed an agreement for the exclusive distribution and manufacturing of various minimally invasive heart valve products in the Asia-Pacific region.

Hong Kong-based OrbusNeich Medical and P+F Products + Features have signed an agreement for the exclusive distribution and manufacturing of various minimally invasive heart valve products in the Asia-Pacific region.

The companies plan to cover countries, including China, Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia, and New Zealand.

The deal includes a series of P+F’s innovative minimally invasive heart valve products premounted on the delivery system, using its dry valve technology.

As part of the agreement, the portfolio, comprising the TricValve Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather Valve, along with transcatheter solutions for pulmonary and mitral valve disease, and endovascular grafts will be distributed.

The TricValve Transcatheter Bicaval Valves consists of two self-expanding biological valves used for treating patients with hemodynamically relevant tricuspid insufficiency and caval reflux.

The system is aimed at patients who are at extreme risk or unsuitable for open-heart surgery.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Designed to treat severe aortic stenosis in patients with a medium to high risk for open-heart surgery, the Vienna Aortic Self-Expandable Transcatheter Valve replaces the native aortic valve. The procedure does not require concomitant surgical removal.

P+F CEO Katharina Kiss said: “My mission as a cardiologist is not only to save lives but to ensure the maximum quality of life for each of our patients and I am convinced that with the joint efforts of this newly founded Asian joint venture, we will be able to revolutionise the medical landscape.”

The TricValve Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather Valve are awaiting CE mark approval.

OrbusNeich chairman, president, and CEO David Chien said: “Our unique product line for percutaneous transcatheter based therapeutics will result in significant improvement of health-related quality of life to our patients, which is an important measure of procedural success in the elderly.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU